MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/cvr/cvae094

Медицинская библиотека · Cardiovascular research · 2024

Gene therapy with phosphodiesterases 2A and 4B ameliorates heart failure and arrhythmias by improving subcellular cAMP compartmentation.

Pavlaki Nikoleta, Froese Alexander, Li Wener, De Jong Kirstie A, Geertz Birgit, Subramanian Hariharan, Mohagaonkar Sanika, Luo Xiaojing, Schubert Mario, Wiegmann Robert, Margaria Jean Piero, Ghigo Alessandra, Kämmerer Susanne, Hirsch Emilio, El-Armouche Ali, Guan Kaomei, Nikolaev Viacheslav O

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

AIMS: Gene therapy with cardiac phosphodiesterases (PDEs), such as phosphodiesterase 4B (PDE4B), has recently been described to effectively prevent heart failure (HF) in mice. However, exact molecular mechanisms of its beneficial effects, apart from general lowering of cardiomyocyte cyclic adenosine monophosphate (cAMP) levels, have not been elucidated. Here, we studied whether gene therapy with two types of PDEs, namely PDE2A and PDE4B, can prevent pressure-overload-induced HF in mice by acting on and restoring altered cAMP compartmentation in distinct subcellular microdomains.

METHODS AND

RESULTS

HF was induced by transverse aortic constriction followed by tail-vein injection of adeno-associated-virus type 9 vectors to overexpress PDE2A3, PDE4B3, or luciferase for 8 weeks. Heart morphology and function was assessed by echocardiography and histology which showed that PDE2A and especially PDE4B gene therapy could attenuate cardiac hypertrophy, fibrosis, and decline of contractile function. Live cell imaging using targeted cAMP biosensors showed that PDE overexpression restored altered cAMP compartmentation in microdomains associated with ryanodine receptor type 2 (RyR2) and caveolin-rich plasma membrane. This was accompanied by ameliorated caveolin-3 decline after PDE2A3 overexpression, reduced RyR2 phosphorylation in PDE4B3 overexpressing hearts, and antiarrhythmic effects of both PDEs measured under isoproterenol stimulation in single cells. Strong association of overexpressed PDE4B but not PDE2A with RyR2 microdomain could prevent calcium leak and arrhythmias in human-induced pluripotent stem-derived cardiomyocytes with the A2254V mutation in RyR2 causing catecholaminergic polymorphic ventricular tachycardia.

CONCLUSION

Our data indicate that gene therapy with phosphodiesterases can prevent HF including associated cardiac remodelling and arrhythmias by restoring altered cAMP compartmentation in functionally relevant subcellular microdomains.

Для цитирования: Pavlaki Nikoleta, Froese Alexander, Li Wener, De Jong Kirstie A, Geertz Birgit, Subramanian Hariharan, Mohagaonkar Sanika, Luo Xiaojing, Schubert Mario, Wiegmann Robert, Margaria Jean Piero, Ghigo Alessandra, Kämmerer Susanne, Hirsch Emilio, El-Armouche Ali, Guan Kaomei, Nikolaev Viacheslav O. Gene therapy with phosphodiesterases 2A and 4B ameliorates heart failure and arrhythmias by improving subcellular cAMP compartmentation.. Cardiovascular research. 2024. DOI: 10.1093/cvr/cvae094.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.